IQ EQ FUND MANAGEMENT IRELAND Ltd Purchases Shares of 1,185 Veeva Systems Inc. $VEEV

IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new position in shares of Veeva Systems Inc. (NYSE:VEEV) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 1,185 shares of the technology company’s stock, valued at approximately $341,000.

Several other large investors have also recently made changes to their positions in VEEV. Facet Wealth Inc. boosted its holdings in Veeva Systems by 3.3% during the second quarter. Facet Wealth Inc. now owns 1,342 shares of the technology company’s stock worth $381,000 after buying an additional 43 shares in the last quarter. TFB Advisors LLC raised its position in shares of Veeva Systems by 1.2% in the first quarter. TFB Advisors LLC now owns 3,586 shares of the technology company’s stock worth $831,000 after acquiring an additional 44 shares during the period. Triangle Securities Wealth Management boosted its stake in shares of Veeva Systems by 0.8% during the 2nd quarter. Triangle Securities Wealth Management now owns 5,782 shares of the technology company’s stock worth $1,665,000 after acquiring an additional 45 shares in the last quarter. Marks Group Wealth Management Inc grew its position in shares of Veeva Systems by 3.3% during the 1st quarter. Marks Group Wealth Management Inc now owns 1,427 shares of the technology company’s stock valued at $331,000 after acquiring an additional 46 shares during the period. Finally, Harbour Investments Inc. increased its stake in shares of Veeva Systems by 7.6% in the 1st quarter. Harbour Investments Inc. now owns 789 shares of the technology company’s stock valued at $183,000 after purchasing an additional 56 shares in the last quarter. 88.20% of the stock is currently owned by institutional investors and hedge funds.

Veeva Systems Stock Performance

Shares of VEEV stock opened at $286.22 on Thursday. Veeva Systems Inc. has a fifty-two week low of $201.54 and a fifty-two week high of $310.50. The stock’s fifty day moving average is $285.16 and its two-hundred day moving average is $271.63. The firm has a market capitalization of $46.91 billion, a P/E ratio of 58.77, a PEG ratio of 2.25 and a beta of 0.98.

Veeva Systems (NYSE:VEEV) last released its earnings results on Wednesday, August 27th. The technology company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.90 by ($0.64). The business had revenue of $789.08 million for the quarter, compared to analysts’ expectations of $768.49 million. Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.Veeva Systems’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.62 EPS. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. On average, equities analysts forecast that Veeva Systems Inc. will post 4.35 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Mizuho increased their price target on Veeva Systems from $295.00 to $325.00 and gave the stock an “outperform” rating in a research report on Friday, August 29th. BTIG Research reaffirmed a “buy” rating and set a $340.00 target price on shares of Veeva Systems in a research note on Friday, October 17th. UBS Group lifted their price target on shares of Veeva Systems from $285.00 to $310.00 and gave the company a “neutral” rating in a research note on Thursday, August 28th. Weiss Ratings restated a “hold (c+)” rating on shares of Veeva Systems in a research report on Wednesday, October 8th. Finally, Truist Financial increased their price objective on shares of Veeva Systems from $268.00 to $275.00 and gave the company a “hold” rating in a report on Thursday, August 28th. Seventeen research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Veeva Systems presently has a consensus rating of “Moderate Buy” and a consensus target price of $307.58.

Insider Buying and Selling at Veeva Systems

In other Veeva Systems news, SVP Jonathan Faddis sold 720 shares of the firm’s stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $298.12, for a total value of $214,646.40. Following the transaction, the senior vice president directly owned 7,868 shares of the company’s stock, valued at $2,345,608.16. This trade represents a 8.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 7th. The shares were sold at an average price of $306.62, for a total value of $1,839,720.00. Following the completion of the sale, the insider owned 25,325 shares of the company’s stock, valued at $7,765,151.50. This trade represents a 19.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 24,665 shares of company stock worth $7,438,000. Insiders own 10.30% of the company’s stock.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.